Injective Surges 27%, Outperforming NEAR and Sei

Injective Token Surges Amidst ETF Filings and Supply Reduction Efforts

The Injective network’s native token, INJ, experienced a significant surge on October 16, 2026, with its price climbing between 23% and 28% within a 24-hour period, pushing intraday values above $9.10. This performance outpaced other prominent layer-1 networks, including NEAR, Sei, and Cosmos Hub. A notable increase in trading volume accompanied the price jump, indicating substantial market interest beyond minor order book adjustments.

ETF Filings Drive Momentum

The primary catalyst for this upward trend appears to be the actions of asset manager 21Shares. Around September 18, 2026, 21Shares amended its filing for an Injective Exchange Traded Fund (ETF). This proposed product would directly hold INJ tokens, diverging from strategies that rely on derivatives. Furthermore, the ETF would incorporate discretionary staking capabilities, with 21Shares targeting a Nasdaq listing under the ticker TINJ.

21Shares is not alone in pursuing an INJ ETF. Canary Capital and REX-Osprey have also advanced their own filings for staked versions of an INJ ETF, which could potentially stake up to 90% of their holdings.

Broader Gains and Supply Mechanics

The recent 24-hour spike is part of a larger rally, with INJ having gained approximately 67% to 70% over the past 30 days. A significant factor contributing to this sustained growth is the token’s supply mechanics. In January 2026, the Injective community approved IIP-617, a governance proposal designed to facilitate ongoing supply contraction for INJ.

Injective’s revenue-to-fully diluted valuation ratio is reportedly around 0.95, the highest among layer-1 networks, reportedly surpassing established players like Solana and Arbitrum.

Real-World Asset Integration and Investor Access

The Injective ecosystem is also attracting interest from the real-world asset sector, with a Canadian mortgage firm planning to integrate a substantial real estate portfolio onto the Injective chain.

The potential approval of staked INJ ETFs by regulators could open the token to a new class of investors who might otherwise avoid direct engagement with cryptocurrency exchanges. The proposed ETFs from 21Shares, Canary Capital, and REX-Osprey could serve as a gateway for such investors.

Staking and Supply Dynamics

The staking aspect of these proposed ETFs warrants particular attention. A fund that stakes as much as 90% of its assets would effectively lock up a significant portion of INJ tokens. When combined with the supply reduction mechanisms introduced by IIP-617, this could lead to a further tightening of available supply.

Key Factors to Monitor

Moving forward, several key developments will be crucial to track. These include regulatory responses to the 21Shares TINJ filing and the competing staked ETF applications, the sustainability of trading volume following the initial surge, and whether on-chain activity keeps pace with the market valuation that has recently been established.